SG11202101255UA - Diazabicyclooctanones as inhibitors of serine beta-lactamases - Google Patents
Diazabicyclooctanones as inhibitors of serine beta-lactamasesInfo
- Publication number
- SG11202101255UA SG11202101255UA SG11202101255UA SG11202101255UA SG11202101255UA SG 11202101255U A SG11202101255U A SG 11202101255UA SG 11202101255U A SG11202101255U A SG 11202101255UA SG 11202101255U A SG11202101255U A SG 11202101255UA SG 11202101255U A SG11202101255U A SG 11202101255UA
- Authority
- SG
- Singapore
- Prior art keywords
- diazabicyclooctanones
- lactamases
- inhibitors
- serine beta
- serine
- Prior art date
Links
- XQDYOPKCGHWFBY-UHFFFAOYSA-N 1-cyclooctyl-1,3-diazocan-2-one Chemical class O=C1NCCCCCN1C1CCCCCCC1 XQDYOPKCGHWFBY-UHFFFAOYSA-N 0.000 title 1
- 108020004256 Beta-lactamase Proteins 0.000 title 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 title 1
- 102000006635 beta-lactamase Human genes 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18290093.6A EP3608318A1 (en) | 2018-08-09 | 2018-08-09 | Diaazabicyclooctanone derivatives as antibacterials |
| EP18213635.8A EP3670512A1 (en) | 2018-12-18 | 2018-12-18 | Diazabicyclooctanones as inhibitors of serine beta-lactamases |
| PCT/EP2019/071370 WO2020030761A1 (en) | 2018-08-09 | 2019-08-08 | Diazabicyclooctanones as inhibitors of serine beta-lactamases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202101255UA true SG11202101255UA (en) | 2021-03-30 |
Family
ID=67667824
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202101255UA SG11202101255UA (en) | 2018-08-09 | 2019-08-08 | Diazabicyclooctanones as inhibitors of serine beta-lactamases |
Country Status (22)
| Country | Link |
|---|---|
| EP (2) | EP4272831A3 (en) |
| JP (1) | JP7429988B2 (en) |
| KR (1) | KR20210055701A (en) |
| CN (2) | CN111954671B (en) |
| AU (1) | AU2019318115B2 (en) |
| BR (1) | BR112021002311A2 (en) |
| CA (1) | CA3110111A1 (en) |
| DK (1) | DK3833665T3 (en) |
| ES (1) | ES2960952T3 (en) |
| FI (1) | FI3833665T3 (en) |
| HR (1) | HRP20231228T1 (en) |
| HU (1) | HUE063324T2 (en) |
| IL (1) | IL280770B2 (en) |
| LT (1) | LT3833665T (en) |
| MX (1) | MX2021001564A (en) |
| PL (1) | PL3833665T3 (en) |
| RS (1) | RS64679B1 (en) |
| SG (1) | SG11202101255UA (en) |
| SI (1) | SI3833665T1 (en) |
| TW (1) | TWI764030B (en) |
| WO (1) | WO2020030761A1 (en) |
| ZA (1) | ZA202100906B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111943950B (en) * | 2020-09-10 | 2022-03-29 | 山东安信制药有限公司 | Preparation method of rilibatan |
| CN115605480B (en) * | 2021-05-07 | 2024-04-05 | 宁夏农林科学院 | Sulfonylamide-substituted compounds and their use as beta-lactamase inhibitors |
| CN115448920A (en) * | 2022-10-14 | 2022-12-09 | 广州楷石医药有限公司 | Beta-lactamase inhibitor and application thereof |
| CN117700415B (en) * | 2024-02-06 | 2024-04-30 | 成都四面体药物研究有限公司 | Carbamide-containing bicyclic compound, application thereof, medicine prepared from carbamide-containing bicyclic compound, combined medicine of carbamide-containing bicyclic compound and compound preparation of carbamide-containing bicyclic compound |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA101966C2 (en) * | 2008-01-18 | 2013-05-27 | Мерк Шарп Енд Доме Корп. | Beta-lactamase inhibitors |
| WO2013030735A1 (en) * | 2011-08-30 | 2013-03-07 | Wockhardt Limited | 1,6- diazabicyclo [3,2,1] octan- 7 - one derivatives and their use in the treatment of bacterial infections |
| AR090539A1 (en) * | 2012-04-02 | 2014-11-19 | Astrazeneca Ab | INHIBITING COMPOUNDS OF B LACTAMASA |
| UA111925C2 (en) * | 2012-12-11 | 2016-06-24 | Федора Фармасьютікалз Інк. | BICYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND β-LACTAMASE INHIBITORS |
| GB201310542D0 (en) | 2013-06-13 | 2013-07-31 | Antabio Sas | Compounds |
| GB2533136A (en) | 2014-12-11 | 2016-06-15 | Antabio Sas | Compounds |
| MA49623A (en) | 2017-07-21 | 2021-03-17 | Antabio Sas | CHEMICAL COMPOUNDS |
| CN107501265B (en) * | 2017-10-09 | 2019-05-28 | 台州职业技术学院 | A kind of 7- oxo-diazabicylo [3,2,1] octane derivatives compound and its preparation method and application |
| WO2019093450A1 (en) * | 2017-11-10 | 2019-05-16 | 塩野義製薬株式会社 | Diazabicyclooctane derivative |
-
2019
- 2019-08-08 AU AU2019318115A patent/AU2019318115B2/en active Active
- 2019-08-08 DK DK19755850.5T patent/DK3833665T3/en active
- 2019-08-08 EP EP23180712.4A patent/EP4272831A3/en active Pending
- 2019-08-08 HU HUE19755850A patent/HUE063324T2/en unknown
- 2019-08-08 BR BR112021002311-9A patent/BR112021002311A2/en unknown
- 2019-08-08 CN CN201980014933.7A patent/CN111954671B/en active Active
- 2019-08-08 KR KR1020217007060A patent/KR20210055701A/en active Search and Examination
- 2019-08-08 TW TW108128294A patent/TWI764030B/en active
- 2019-08-08 EP EP19755850.5A patent/EP3833665B1/en active Active
- 2019-08-08 MX MX2021001564A patent/MX2021001564A/en unknown
- 2019-08-08 CN CN202311024006.8A patent/CN117384155A/en active Pending
- 2019-08-08 JP JP2021506575A patent/JP7429988B2/en active Active
- 2019-08-08 IL IL280770A patent/IL280770B2/en unknown
- 2019-08-08 FI FIEP19755850.5T patent/FI3833665T3/en active
- 2019-08-08 CA CA3110111A patent/CA3110111A1/en active Pending
- 2019-08-08 SG SG11202101255UA patent/SG11202101255UA/en unknown
- 2019-08-08 WO PCT/EP2019/071370 patent/WO2020030761A1/en active Application Filing
- 2019-08-08 LT LTEPPCT/EP2019/071370T patent/LT3833665T/en unknown
- 2019-08-08 ES ES19755850T patent/ES2960952T3/en active Active
- 2019-08-08 RS RS20230929A patent/RS64679B1/en unknown
- 2019-08-08 SI SI201930627T patent/SI3833665T1/en unknown
- 2019-08-08 HR HRP20231228TT patent/HRP20231228T1/en unknown
- 2019-08-08 PL PL19755850.5T patent/PL3833665T3/en unknown
-
2021
- 2021-02-10 ZA ZA2021/00906A patent/ZA202100906B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN117384155A (en) | 2024-01-12 |
| DK3833665T3 (en) | 2023-10-09 |
| SI3833665T1 (en) | 2023-12-29 |
| EP3833665B1 (en) | 2023-07-19 |
| ZA202100906B (en) | 2023-07-26 |
| IL280770A (en) | 2021-04-29 |
| RS64679B1 (en) | 2023-11-30 |
| BR112021002311A2 (en) | 2021-05-04 |
| WO2020030761A1 (en) | 2020-02-13 |
| AU2019318115A1 (en) | 2021-03-11 |
| ES2960952T3 (en) | 2024-03-07 |
| AU2019318115B2 (en) | 2024-04-18 |
| PL3833665T3 (en) | 2023-12-27 |
| IL280770B1 (en) | 2024-01-01 |
| TW202019929A (en) | 2020-06-01 |
| IL280770B2 (en) | 2024-05-01 |
| EP4272831A2 (en) | 2023-11-08 |
| CN111954671A (en) | 2020-11-17 |
| MX2021001564A (en) | 2021-05-12 |
| EP4272831A3 (en) | 2024-02-21 |
| KR20210055701A (en) | 2021-05-17 |
| EP3833665A1 (en) | 2021-06-16 |
| LT3833665T (en) | 2023-11-10 |
| JP2021534095A (en) | 2021-12-09 |
| FI3833665T3 (en) | 2023-10-09 |
| TWI764030B (en) | 2022-05-11 |
| JP7429988B2 (en) | 2024-02-09 |
| CA3110111A1 (en) | 2020-02-13 |
| HRP20231228T1 (en) | 2024-01-19 |
| CN111954671B (en) | 2023-09-01 |
| HUE063324T2 (en) | 2024-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL282535A (en) | Substituted 6-azabenzimidazole compounds as hpk1 inhibitors | |
| IL268030A (en) | Bicyclic compounds as allosteric shp2 inhibitors | |
| HK1246164A1 (en) | Substituted pyrazole compounds as serine protease inhibitors | |
| EP4069212A4 (en) | Inhibitors of hif-2alpha | |
| EP3801503A4 (en) | Inhibitors of sarm1 | |
| ZA202100906B (en) | Diazabicyclooctanones as inhibitors of serine beta-lactamases | |
| EP3906029A4 (en) | Inhibitors of menin-mll interaction | |
| EP3609882A4 (en) | Heterocyclic inhibitors of pcsk9 | |
| IL269695A (en) | Compounds useful as inhibitors of alcat 1 | |
| SG11202008925VA (en) | Inhibitors of micro-rna 22 | |
| EP3801499A4 (en) | Inhibitors of sarm1 | |
| EP3749365A4 (en) | Peptidyl inhibitors of calcineurin-nfat interaction | |
| IL276312A (en) | Use of alkoxypyrazoles as nitrification inhibitors | |
| IL308476A (en) | Inhibitors of the menin-mll interaction | |
| EP3801500A4 (en) | Inhibitors of sarm1 | |
| EP3801525A4 (en) | Inhibitors of prolyl-trna-synthetase | |
| IL266223A (en) | Prodrugs of kallikrein inhibitors | |
| IL277866B1 (en) | Substituted aminothiazoles as inhibitors of nucleases | |
| IL283295A (en) | Inhibitors of gli1 as therapeutic agents | |
| IL277869A (en) | Substituted propanamides as inhibitors of nucleases | |
| PT3833665T (en) | Diazabicyclooctanones as inhibitors of serine beta-lactamases | |
| AU2018901681A0 (en) | Inhibitors of necroptosis | |
| AU2017900935A0 (en) | Heterocyclic inhibitors of PCSK9 | |
| AU2017904351A0 (en) | Inhibitors of necroptosis |